Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking

Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group

The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions

Cipla EU to form JV in USA

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies

Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.